Randomized Phase 2 Trial of ACP-196 and Pembrolizumab Immunotherapy Dual Checkpoint Inhibition in Platinum Resistant Metastatic Urothelial Carcinoma
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Acerta Pharma
Start Date
May 1, 2015
End Date
May 8, 2019
Administered By
Duke Cancer Institute
Awarded By
Acerta Pharma
Start Date
May 1, 2015
End Date
May 8, 2019